OBJECTIVE: . To investigate the services offered to patients with AS in the UK in 2010. METHODS: Two thousand non-health-care professional members of the National Ankylosing Spondylitis Society (NASS) were sent a questionnaire asking about their experiences surrounding diagnosis, treatment and access to therapies (response rate 40%). A separate questionnaire was sent to a consultant rheumatologist in every acute NHS trust in the UK, asking about services offered to patients with AS (response rate 68%). RESULTS: Overall, there was a mean diagnostic delay of 8.57 years. Almost one-third (32.2%) of patients were not reviewed in secondary care. Non-attendance was associated with increasing age and longer disease duration. Twenty per cent of patients were taking anti-TNF drugs, but 18.8% of departments reported that their ability to give anti-TNF therapy was restricted (64% reported primary-care trust rationing and 14% lack of staff). Almost all rheumatology departments had access to MRI, but 70.9% still used X-ray radiographs as their first-line investigation. A minority (5.6%) of patients reported they had never seen a physiotherapist, but less than one-third could self-refer for treatment during a flare. CONCLUSION: This is the first study to explore the services available to people with AS in the UK. Almost one-third of patients are not seen in rheumatology departments and therefore may be under-treated. For those who are seen, access to anti-TNF drugs and other therapies remains an issue.
OBJECTIVE: . To investigate the services offered to patients with AS in the UK in 2010. METHODS: Two thousand non-health-care professional members of the National Ankylosing Spondylitis Society (NASS) were sent a questionnaire asking about their experiences surrounding diagnosis, treatment and access to therapies (response rate 40%). A separate questionnaire was sent to a consultant rheumatologist in every acute NHS trust in the UK, asking about services offered to patients with AS (response rate 68%). RESULTS: Overall, there was a mean diagnostic delay of 8.57 years. Almost one-third (32.2%) of patients were not reviewed in secondary care. Non-attendance was associated with increasing age and longer disease duration. Twenty per cent of patients were taking anti-TNF drugs, but 18.8% of departments reported that their ability to give anti-TNF therapy was restricted (64% reported primary-care trust rationing and 14% lack of staff). Almost all rheumatology departments had access to MRI, but 70.9% still used X-ray radiographs as their first-line investigation. A minority (5.6%) of patients reported they had never seen a physiotherapist, but less than one-third could self-refer for treatment during a flare. CONCLUSION: This is the first study to explore the services available to people with AS in the UK. Almost one-third of patients are not seen in rheumatology departments and therefore may be under-treated. For those who are seen, access to anti-TNF drugs and other therapies remains an issue.
Authors: Andrew Keat; Alexander N Bennett; Karl Gaffney; Helena Marzo-Ortega; Raj Sengupta; Tamara Everiss Journal: Rheumatol Int Date: 2016-12-29 Impact factor: 2.631
Authors: Roxanne Cooksey; Muhammad J Husain; Sinead Brophy; Helen Davies; Muhammad A Rahman; Mark D Atkinson; Ceri J Phillips; Stefan Siebert Journal: PLoS One Date: 2015-07-17 Impact factor: 3.240
Authors: Georgios Lyratzopoulos; Silvia C Mendonca; Carolynn Gildea; Sean McPhail; Michael D Peake; Greg Rubin; Hardeep Singh; William Hamilton; Fiona M Walter; Martin Roland; Gary A Abel Journal: Br J Gen Pract Date: 2017-12-18 Impact factor: 5.386
Authors: Marco Garrido-Cumbrera; Ottfrid Hillmann; Raj Mahapatra; David Trigos; Petra Zajc; Luisa Weiss; Galya Bostynets; Laure Gossec; Laura C Coates Journal: Rheumatol Ther Date: 2017-06-09
Authors: Rebecca J Stack; Christian D Mallen; Chris Deighton; Patrick Kiely; Karen L Shaw; Alison Booth; Kanta Kumar; Susan Thomas; Ian Rowan; Rob Horne; Peter Nightingale; Sandy Herron-Marx; Clare Jinks; Karim Raza Journal: Health Expect Date: 2014-06-03 Impact factor: 3.377
Authors: Roxanne Cooksey; Sinead Brophy; Muhammad Jami Husain; Elizabeth Irvine; Helen Davies; Stefan Siebert Journal: BMC Musculoskelet Disord Date: 2012-12-10 Impact factor: 2.362